Latest filings (excl ownership)
15-12G
Securities registration termination
1 Dec 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Nov 22
8-K
Entry into a Material Definitive Agreement
21 Nov 22
25-NSE
Exchange delisting
21 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
18 Nov 22
DEFA14A
Additional proxy soliciting materials
7 Nov 22
8-K
Other Events
7 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
3 Nov 22
DEFM14A
Proxy related to merger
7 Oct 22
PREM14A
Preliminary proxy related to merger
21 Sep 22
8-K
Regulation FD Disclosure
13 Sep 22
DEFA14A
Additional proxy soliciting materials
23 Aug 22
8-K
Entry into a Material Definitive Agreement
23 Aug 22
DEFA14A
Additional proxy soliciting materials
23 Aug 22
DEFA14A
Additional proxy soliciting materials
22 Aug 22
8-K
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
22 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4 Aug 22
8-K
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
1 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 22
8-K
Regulation FD Disclosure
8 Jun 22
8-K
Regulation FD Disclosure
25 May 22
8-K
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
24 May 22
10-Q
2022 Q1
Quarterly report
5 May 22
8-K
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5 May 22
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
8-K
Regulation FD Disclosure
11 Apr 22
8-K
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
18 Mar 22
S-8
Registration of securities for employees
11 Mar 22
8-K
Departure of Directors or Certain Officers
4 Mar 22
8-K
Departure of Directors or Certain Officers
2 Mar 22
Latest ownership filings
SC 13G/A
Flynn James E
10 Feb 23
4
Julie McHugh
21 Nov 22
4
BENJAMIN F MCGRAW III
21 Nov 22
4
Peter J McDonnell
21 Nov 22
4
Casey C. Kopczynski
21 Nov 22
4
Peter Frederick Lang
21 Nov 22
4
John LaRocca
21 Nov 22
4
DAVID W GRYSKA
21 Nov 22
4
Toit Michael du
21 Nov 22
4
Richard Croarkin
21 Nov 22
4
Jeffrey Calabrese
21 Nov 22
4
RAJ KANNAN
21 Nov 22
SC 13G/A
MORGAN STANLEY
10 Nov 22
4
Jeffrey Calabrese
3 Nov 22
4
John LaRocca
16 Aug 22
4
Jeffrey Calabrese
16 Aug 22
4
Jeffrey Calabrese
13 Jul 22
4
Jeffrey Calabrese
6 Jul 22
4
Julie McHugh
13 Jun 22
4
BENJAMIN F MCGRAW III
13 Jun 22
4
Peter J McDonnell
13 Jun 22
4
DAVID W GRYSKA
13 Jun 22
4
Toit Michael du
13 Jun 22
4
Richard Croarkin
13 Jun 22
4
Casey C. Kopczynski
22 Mar 22
4
John LaRocca
22 Mar 22
4
RAJ KANNAN
22 Mar 22
4
Peter Frederick Lang
22 Mar 22
3
Peter Frederick Lang
22 Mar 22
4
BENJAMIN F MCGRAW III
2 Mar 22
4
John LaRocca
23 Feb 22
SC 13G/A
PFM Health Sciences, LP
14 Feb 22
SC 13G/A
Flynn James E
11 Feb 22
4
Casey C. Kopczynski
9 Feb 22
4
John LaRocca
9 Feb 22
4
THOMAS A MITRO
9 Feb 22
SC 13G/A
VANGUARD GROUP INC
9 Feb 22
SC 13G
MORGAN STANLEY
9 Feb 22
4
David Hollander
8 Feb 22
4
Casey C. Kopczynski
8 Feb 22